Hepatitis B IG

Hepatitis B immune globulin (Bayhep B, Hyper Hep B, Nabi-HB, HepaGamB)

OFFICE ADMINISTRATION

Indications for Prior Authorization:

• Post exposure prophylaxis
  • Acute exposure to blood positive for hepatitis B surface antigen (HBsAg)
  • Perinatal exposure of infants born to HBsAg positive mothers
  • Sexual exposure to an HBsAg positive person
  • Household exposure to people with acute HBV infection
• Hepatitis B prophylaxis post-liver transplantation

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

• Prophylaxis of household contacts of people with acute hepatitis B is not indicated unless they have had identifiable blood exposure to the infected person. If so they should be treated like those with sexual exposure

Dosing:

Post-exposure prophylaxis

• 0.06 ml/kg IM immediately after exposure, then repeat in 30 days

Perinatal exposure of infants

• 0.5 ml IM preferable within 12 hours of birth, then repeat at 3 months of age

Sexual exposure to an HBsAg positive person

• 0.06 ml/kg IM within 14 days of sexual contact

Household exposure to people with acute HBV infection

• 0.5 ml IM for infants less then 12 months of age who have been exposed to a primary care giver with acute hepatitis B

HBIG post-liver transplant in Hepatitis B positive patients

• 10,000 IU, IV pre-operatively, then
• 10,000 IU, IV for 6 days, then
• 10,000 IU, IV every 4-6 weeks for life

Approval:

• Post-exposure prophylaxis: one month
• Perinatal exposure of infants: up to six months
• Sexual exposure: 14 days
• Household exposure: one month
• HBIG post-liver transplant in Hepatitis B positive patient: indefinitely